CT 32228 | CAS# 521064-34-6 | control

MedKoo Cat#: 413368 | Name: CT 32228

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CT 32228 is the inactive isomer of CT-32228 used as a control.

Chemical Structure

CT 32228

CAS#521064-34-6

Theoretical Analysis

MedKoo Cat#: 413368

Name: CT 32228

CAS#: 521064-34-6

Chemical Formula: C16H13BrClN5

Exact Mass: 389.0043

Molecular Weight: 390.67

Elemental Analysis: C, 49.19; H, 3.35; Br, 20.45; Cl, 9.07; N, 17.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CT 32228; CT-32228; CT32228

IUPAC/Chemical Name

1,3,5-Triazine-2,4-diamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-

InChi Key

NUPGPJBRKLLVNK-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H13BrClN5/c1-9-2-5-11(18)8-13(9)14-21-15(19)23-16(22-14)20-12-6-3-10(17)4-7-12/h2-8H,1H3,(H3,19,20,21,22,23)

SMILES Code

NC1=NC(C2=CC(Cl)=CC=C2C)=NC(NC3=CC=C(Br)C=C3)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 390.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Douvas MG, Hogan KN, Ji Y, Hollenback D, Bonham L, Singer JW, Mitchell BS. Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res. 2006 Aug;30(8):1027-36. doi: 10.1016/j.leukres.2005.11.018. Epub 2006 Feb 20. PMID: 16488473. 2: Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Jul 1;11(13):4857-66. doi: 10.1158/1078-0432.CCR-04-2352. PMID: 16000584. 3: Bonham L, Leung DW, White T, Hollenback D, Klein P, Tulinsky J, Coon M, de Vries P, Singer JW. Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis. Expert Opin Ther Targets. 2003 Oct;7(5):643-61. doi: 10.1517/14728222.7.5.643. PMID: 14498826. 4: Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res. 2005 Oct 15;65(20):9415-25. doi: 10.1158/0008-5472.CAN-05-0516. Erratum in: Cancer Res. 2005 Dec 15;65(24):11785. PMID: 16230405. 5: La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res. 2006 Nov 1;12(21):6540-6. doi: 10.1158/1078-0432.CCR-06-0140. PMID: 17085669.